Malarone Pediátrico

Atovaquone/proguanil, the active ingredient in Malarone Pediátrico, is an antimalarial presented as an oral tablet for pediatric use. It provides both prophylaxis and treatment of uncomplicated malaria caused by Plasmodium species in children and adolescents.

GNH USA supplies Malarone Pediátrico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions, offering reliable antimalarial therapy for children.

Malarone Pediátrico, a combination antimalarial, is indicated for malaria prophylaxis and treatment.

- Prophylaxis of malaria: prevents Plasmodium infection in children traveling to endemic areas. - Treatment of acute uncomplicated malaria: clears parasitemia in pediatric patients with P. falciparum or other species. - Post‑exposure prophylaxis: reduces risk of malaria after a known mosquito bite in an endemic region.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the abdomen. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe neutropenia: marked reduction in white blood cells. - Anaphylaxis: rapid onset allergic reaction with breathing difficulty. - Hemolysis: breakdown of red blood cells, especially in susceptible individuals.

Before prescribing Malarone Pediátrico, consider the following precautions: - Assess G6PD deficiency: consider alternative therapy in severe deficiency. - Hypersensitivity: avoid in patients with known allergy to atovaquone or proguanil. - Hepatic impairment: use with caution and monitor liver function. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Malarone Pediátrico may interact with several medicines. Review patient medication lists carefully.

Major Interactions (Avoid): - Rifampin: reduces atovaquone plasma concentrations, decreasing efficacy. - Cimetidine: may increase atovaquone levels, raising risk of toxicity. - Protease inhibitors (e.g., ritonavir): can lower drug effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Phenytoin: may decrease proguanil levels, reducing therapeutic benefit. - Oral contraceptives: may reduce hormonal efficacy, advise additional contraception.